myirislogo
28 November, 2014 13:55 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
State Bank O 319.85 4.58
Tata Motors 531.75 2.55
Tata Stl 471.80 2.45
Bhel 283.00 0.00
Reliance 1003.45 1.65
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Arvind Remedies Limited
Arvind Remedies Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:531823NSE:ARVINDREMBloomberg:ARR@INReuters:ARRE.BO
Market Lot: 1Face Value: 10ISIN Demat: INE211C01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
16-JUN-14 Arvind Remedies announced today that the company signed memorandum of understanding (MoU) with Adesh University, Punjab, to transfer the patent right to the company for manufacturing and marketing of formulation product from botanical source for treatment of Type 2, diabetes, coronary heart disease, neuro and anti depression. 28-MAY-14 Arvind Remedies announced that the company has signed Memorandum of Understanding (MoU) with SRM Un...   More..
Business Profile Future Plans
CEO Talk
Arvind Remedies expects its turnover to grow 20-30 per cent in the current fiscal, while net profit is likely to jump substantially. The company`s herbal division is expected to register a 40 per cent growth in turnover during the next three years, while allopathic division will grow 15 per cent.   Arvind Shah
One To One
Recent news
Latest News
Arvind Remedies, Adesh University to launch new drugs  -IRIS 16-Jun-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2014 (12)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 9104.866632.604365.67
Other Income4.655.933.88
Total Income9109.516638.534369.54
Cost of goods sold7341.695305.283688.43
OPBDIT1767.821333.25681.12
PAT588.99406.17194.10
Gross Block---
Equity capital681.26482.30482.30
EPS (Rs.)10.028.420.40
DPS (Rs.)---
BV (Rs.)---
P/E range (x)2.64 - 5.980.26 - 4.764.50 - 7.50
Debt / Equity (x)---
Operating margin (% of OI)19.420.115.6
Net margin (% of OI) 6.5 6.1 4.4
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
190, Poonamallee High Road
Chennai
Tamil Nadu-600 084
PHONE
(044) 2641 4788/ 89
FAX
(044) 2642 3296
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer